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Abstract The MHC controls specificity, to ensure that appro-
priate immune responses are mounted to invading pathogens
whilst maintaining tolerance to the host. It encodes molecules
that act as sentinels, providing a snapshot of the health of the
interior and exterior of the cell for immune surveillance. To
maintain the ability to respond appropriately to any disease
requires a delicate balance of expression and function, and
many subtleties of the system have been described at the gene,
individual and population level. The main players are the high-
ly polymorphic classical MHC class I and class II molecules,
as well as some non-classical loci of both types. Transporter
associated with antigen processing (TAP) peptide transporters,
proteasome components and Tapasin, encoded within the
MHC, are also involved in selection of peptide for presenta-
tion. The plethora of mechanisms microorganisms use to sub-
vert immune recognition, through blocking these antigen pro-
cessing and presentation pathways, attests to the importance of
HLA in resistance to infection. There is continued interest in
MHC genetics in its own right, as well as in relation to KIR, to
transplantation, infection, autoimmunity and reproduction.
Also of topical interest, cancer immunotherapy through check-
point inhibition depends on highly specific recognition of can-
cer peptide antigen and continued expression of HLA mole-
cules. Here, we briefly introduce some background to the
MHC/KIR axis in man. This special issue of immunogenetics
expands on these topics, in humans and other model species.
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Introduction
HLA is the earliest and most widespread example of
personalised medicine, in relation to transplantation biology.
It is also the region of the genome associated genetically with
more diseases than any other, including infectious conditions,
but particularly autoimmunity. Resistance to disease is thought
to drive the extreme polymorphism of HLA, but other mecha-
nisms have been proposed. In the last two decades, attention
has turned to unexpected roles for MHC molecules such as in
modelling of synapses (Shatz 2009) and, as discussed in this
volume by Colucci and by Persson et al., pregnancy. In support
of the former, many different microbial species, particularly
viruses and bacteria, elaborate proteins that block antigen pro-
cessing and presentation. The human MHC encompasses over
200 genes, at least 50 of which have functions in immune
defence. They include the following: three classical and three
non-classical class I loci, plus several pseudogenes; four clas-
sical and two non-classical class II loci, each comprising two
genes (A and B chains); four complement components; two
immune regulators; 10 genes involved in inflammation or ac-
tivation of NK cells; three genes involved in stress responses;
six genes to do with leukocyte maturation; five genes encoding
antigen processing elements; and two other IgSF molecules.
Transplantation is discussed in this volume in relation to
allorecognition and viruses by Frans Claas.
Class I processing and presentation
MHC class I molecules have evolved mainly to present pep-
tides from pathogens that replicate within host cells, in
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particular viruses. The presence of three classical class I
isotypes HLA-A, HLA-B and HLA-C, with different
peptide-binding characteristics, ensures that pathogens with
different protein coding capacity remain visible to the immune
system. Alleles of all three isotypes utilise a common pathway
for peptide loading. In brief, protein from the pathogen is first
degraded in the cytosol, and the resulting peptides are then
translocated into the endoplasmic reticulum. Here, they are
loaded onto class I molecules before transit to the cell surface
for presentation to cytotoxic CD8 T cells.
The proteasome, a cytosolic protease, is largely responsible
for generating the peptides that eventually bind class I mole-
cules. It comes in various forms. In many cell types, MHC
peptide presentation is linked to constitutive protein turnover
and is undertaken by a proteasome that utilises three catalytic
subunits termed β1, β2 and β5. In professional antigen pre-
senting cells, or in the presence of interferon, these subunits
can be exchanged for βi, β2i and β5i to produce an
immunoproteasome, which tailors peptides for MHC binding
(Gaczynska et al. 1993). The immunoproteasome has altered
specificity and preferentially generates peptides with C-
terminal hydrophobic or basic residues. These amino acids
are used by the majority of class I alleles to anchor the C-
terminus of the peptide into the MHC molecule (Gaczynska
et al. 1993; Young et al. 1995). The subunit composition of the
immunoproteasome can be further modified by substitution of
β5i with β5t to generate the thymoproteasome. The β5t sub-
unit confers reduced chymotrypsin-like activity thereby
influencing the generation of peptides with hydrophobic
C-terminal residues, amino acids favoured by 90% of
MHC alleles (Takahama et al. 2008). Expression of the
thymoproteasome by thymic cortical epithelial cells may as-
sist thymic education by generating fewer high affinity pep-
tides and in doing so prevent excessive loss of T cells through
negative selection (Takahama et al. 2008; Tomaru et al. 2009).
Once generated by the proteasome, peptides must be rap-
idly transported into the endoplasmic reticulum to escape the
activity of cytosolic aminopeptidases, which would otherwise
lead to their rapid degradation (Reits et al. 2003). This is
mediated by the transporter associated with antigen process-
ing (TAP), a heterodimer of TAP1 and TAP2 that is encoded
in the MHC (Kelly et al. 1992). Human TAP preferentially
transports peptides that are 8–12 aa in length (Androlewicz
and Cresswell 1996). In contrast to other species, it is promis-
cuous in the diversity of peptides translocated, and so for
humans, the class I molecule itself largely determines which
peptides are ultimately presented to the immune system
(Androlewicz and Cresswell 1996). Although there is limited
flexibility in the length of peptide that MHC I molecules can
accommodate, those that are too long to bind particular alleles
can be trimmed at the amino-terminus by ER resident pepti-
dases ERAP1 and ERAP2 (Chen et al. 2016). A related en-
zyme, insulin-regulated aminopeptidase (IRAP), performs a
similar function in endosomal compartments and is important
in cross-presentation (Saveanu et al. 2009). In addition to its
transport function, TAP forms the central pillar of the peptide-
loading complex, an assembly of proteins that ensure efficient
loading of peptide onto MHC class I (Blum et al. 2013;
Cresswell et al. 1999; Neefjes et al. 2011). After initial asso-
ciation with calnexin, empty MHC I/β2 enters a complex
comprising TAP, two general folding chaperones, ERp57
and calreticulin, and tapasin, a dedicated class I chaperone
(Cresswell et al. 1999). Tapasin functions to bridge class I
molecules awaiting peptide with TAP and is essential for the
efficient optimization of class I peptide selection (Williams
et al. 2002). A molecular tug-of-war between peptide and
tapasin is the basis of the selection process (Fisette et al.
2016). Tapasin exerts force upon the peptide-binding domain
resulting in opening of the grove and release of low affinity
peptide. High affinity peptide binds strongly to the MHCmol-
ecule and is able to overcome the force exerted by tapasin
resulting in closure of the groove and release of tapasin
(Fisette et al. 2016). Interestingly, some class I alleles optimise
peptide selection in the complete absence of tapasin, possibly
as a mechanism to counter pathogen subversion (Williams
et al. 2002). For these tapasin-independent alleles, peptide
optimization is poorly enhanced when tapasin is present
(Williams et al. 2002). More recently TAPBPR, a second
tapasin-related MHC I chaperone, has been shown to enhance
peptide optimisation and also reduce the diversity of peptides
presented by MHC class I (Hermann et al. 2015). How these
two chaperones cooperate is yet to be determined, but ulti-
mately class I with its peptide cargo arrives at the cell surface
for presentation to T cells. Recently, attention has focused on
the association of certain HLA-B and HLA-C alleles and re-
sistance to disease (Carrington et al. 1999). Whilst this might
be predictable given their role in immune surveillance, an
unexpected correlation with the level of cell surface expres-
sion of HLA-C and prevalence of cytotoxic Tcell responses to
HIV was observed (Apps et al. 2013). Increased surface ex-
pression may correlate with a more focused peptide repertoire
and may be a more general feature of MHC biology than
previously appreciated (Chappell et al. 2015).
The MHC also encodes three non-classical molecules
HLA-E, HLA-F and HLA-G that show limited polymor-
phism, covered here by Persson et al. The best defined of these
is HLA-E which interacts with inhibitory receptors present on
the surface of NK cells to prevent killing but may also present
peptides from microorganisms to T cells (Braud et al. 1998;
van Meijgaarden et al. 2015). It is limited in the diversity of
peptides it can bind, preferentially accommodating peptides
that originate from signal sequences derived from classical
HLA-A, HLA-B and HLA-C (Miller et al. 2003).
Interference in the expression of classical class I molecules,
such as occurs during viral infection, may be detected by
‘missing-self’, or lack of surface HLA-E expression. The
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functions of HLA-F and HLA-G are less well-characterised.
HLA-G expression was first reported in placental trophoblast
cells and a role in acceptance of the foetus ‘allograph’ pro-
posed. Here, HLA-G may influence the function of NK cells
directly by interaction with receptors on NK cells, monocytes
in the form of an HLA-G dimer (Clements et al. 2005), or
indirectly by supporting the expression of surface HLA-E.
Caution has been suggested in interpreting reports of functions
in other settings where consensus on basic issues such as
confirmation of expression is lacking (Apps et al. 2008).
The function of HLA-F is even more enigmatic with proposed
roles in cross-presentation and NK receptor binding (Burian
et al. 2016).
MHC class II processing and presentation
MHC class II molecules represent a second group of surface
receptors whose function is to present peptides to T cells, in
this case various CD4 subsets. There are three classical
isotypes, HLA-DP, HLA-DQ and HLA-DR, each composed
of an alpha and a beta chain, which, with the exception of DR
alpha, show extensive polymorphism. The exact number of
alpha beta pairs expressed by an individual will vary depend-
ing on the number of alleles inherited from parents and their
ability to pair in trans. MHC class II molecules show limited
distribution and constitutive expression is largely limited to
dendritic cells, B cells and cells of the monocyte/
macrophage lineage but can be induced in other cell types
(Unanue et al. 2016). During biosynthesis, alpha and beta
chains assemble in the endoplasmic reticulum with a folding
chaperone, invariant chain (Cresswell 1994). Targeting motifs
encoded in the cytoplasmic tail of invariant chain direct the
complex towards loading compartments termed MIIC
(Neefjes 1999). During trafficking, Ii is sequentially degraded
by proteases leaving a small peptide fragment, CLIP, in the
binding groove. CLIP is exchanged for peptide that is gener-
ated by proteolysis of antigen that enters the endocytic path-
way. Partial unfolding of protein is favoured by the reduction
of inter or intra-molecular disulphide bonds by GILT, a thiol
reductase and more generally by the low pH environment
(Arunachalam et al. 2000). The protein is exposed to proteol-
ysis, by a range of endopeptidases and exopeptidases, many of
which show broad cleavage specificity (Lennon-Dumenil
et al. 2002). Members of the cathepsin family are important
not only for generating antigenic peptide but also for the deg-
radation of invariant chain (Riese et al. 1996). Studies involv-
ing an asparginal endopeptidase suggest that key cleavage
events may control subsequent generation of peptide epitopes
and that proteolysis may not be as redundant as once thought
(Antoniou et al. 2000).
Once generated, antigenic peptide can replace the surrogate
peptide CLIP. This exchange process is facilitated by HLA-
DM, a non-classical class II-related molecule (Kelly et al.
1991; Mellins and Stern 2014). Crystallographic studies have
captured stages in this exchange process (Pos et al. 2012).
Large conformational changes in DR alpha facilitate peptide
dissociation and force incoming peptides to compete with
repositioned DR residues for access to the P2 position and
P1 pocket (Pos et al. 2012). Different alleles show varying
degrees of DM dependency, suggesting pathways for DM-
dependent and DM-independent CLIP exchange (Wieczorek
et al. 2016). Additionally, polymorphic variants of DM show
differential catalytic activity upon different class II substrates
adding further complexity to the system (Alvaro-Benito et al.
2015). DM likely interacts with a natural transition state of
class II, as it samples different conformations and is essential
for efficient peptide loading by some alleles and less so for
others (Wieczorek et al. 2016). As observed in computer-
driven simulations, a natural plasticity in class II underpins
both the DM-dependent and DM-independent exchange
mechanisms (Wieczorek et al. 2016). Peptides loaded onto
MHC class II in the presence and absence of HLA-DM may
adopt different conformations that are recognised by non-
overlapping T cell subsets (Mohan and Unanue 2012). The
latter may escape thymic editing and predispose to autoimmu-
nity (Mohan et al. 2010).
The activity of DM is controlled by DO, a molecule bear-
ing close amino acid and structural similarity to DP, DQ and
DR (Guce et al. 2013; Trowsdale and Kelly 1985). DO re-
quires association with DM to prevent its degradation and
to allow egress from the ER (Liljedahl et al. 1998). It adopts
a conformation similar to HLA-DR when in association with
DM, acting as a substrate mimic to block DM activity until it
reaches a low pH environment (Guce et al. 2013). Under late
endosomal/lysosomal conditions, acid-promoted destruction
of DO occurs releasing free DM (Jiang et al. 2015). The role
of HLA-DO is still controversial but likely involves fine-
tuning of the peptide repertoire presented byMHC II, possibly
by limiting the location of DM activity within the endocytic
pathway or more specifically within the sub-domains of the
multivesicular peptide loading compartment (Denzin and
Cresswell 2013; Jiang et al. 2015; van Lith et al. 2001).
Haplotypes and LD
The HLA region is under extensive linkage disequilibrium,
leading to suggestions that the sets of polymorphic genes on
haplotypes act in concert to coordinate presentation of the
health of cells to the immune system. Just as it may be argued
that by maintaining polymorphic TAP transporters near to
class I genes allows for functional coordination on haplotypes,
alleles of other genes within the MHCmay be tuned as a set to
balance immune responses. In relation to function of NK re-
ceptors, MHC haplotypes form two schools in which alleles
are coordinated (Horowitz et al. 2016)). Other candidate genes
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for coordinated functional linkage include TNF, LTA, C2, C4,
BF, MICA andMICB. This phenomenonmay account at least
in part for the extensive linkage disequilibrium over the region
(Dawkins et al. 1999; Yunis et al. 2003). As new techniques
for rapidly compiling complete MHC sequences replace labo-
rious cloning and assembly more haplotypic relationships be-
tween genes will become evident (Horton et al. 2008; Lenz
et al. 2015; Norman et al. 2016; Norman et al. 2015).
Disease association
More diseases are associated with the MHC than with any
other region of the genome (Lenz et al. 2016; Trowsdale
and Knight 2013). The majority of these are autoimmune
conditions. Two conditions where the MHC has been par-
ticularly informative are included in this volume, namely,
Celiac disease (Sollid) and Arthritis (Kampstra and Toes).
However, since the HLA region is so gene dense, poly-
morphic and spans 4Mbp, it is understandable that other
disorders will be genetically associated. Included are sev-
eral Mendelian disorders, associations of which are ex-
plained as linkage disequilibrium with HLA alleles. An
example is congenital adrenal hyperplasia, which is due
to alleles of the CYP21 genes, in the class III region
(White et al. 1985). It is widely assumed that resistance
to infection is driving the extreme MHC variation, al-
though direct evidence for this is limited. Escape variants
of HIV-1 are consistent with the need for continual nov-
elty in peptide-binding grooves (Moore et al. 2002).
Several viruses down-modulate HLA expression to escape
T cell or NK cell recognition, which attests to its impor-
tance for disease resistance.
Genome-wide association studies (GWAS) for autoim-
mune conditions implicate contributions throughout the
genome, but the MHC remains the most important link,
with a greater effect size (Lenz et al. 2016). These disor-
ders are generally associated with discrete class I or class
II alleles. This is consistent with involvement of specific
peptides. For example, narcolepsy, the sleeping disorder,
is associated with HLA-DQB1*006:02 in at least two dif-
ferent populations (Mignot 1997). The recent finding that
a specific flu vaccine gives rise to narcolepsy in a small
group of young individuals is consistent with a complica-
tion of immune response to the vaccine (Ahmed et al.
2015). Narcolepsy is one of the best examples of a clear
MHC association. It has been difficult to identify key
MHC loci association in other disorders. This is likely
because they may be influenced by more than one HLA
locus. In addition, the gene density over the MHC and the
strong LD make analysis very difficult, unless extremely
large cohorts of patients and controls are studied to gen-
erate sufficient statistical power. For example, sarcoidosis
is an autoimmune disease associated with HLA-
DRB1*003. There are reports of an additional, indepen-
dent association with BTNL2, but these are difficult to
confirm, since the two genes DRB1 and BTNL2 are ad-
jacent (Valentonyte et al. 2005). Most autoimmune condi-
tions are multifactorial and appear to involve many gene
variants as well as environmental effects. Clearly, more
reliable data may be obtained by larger studies. This has
been facilitated recently by imputation of HLA type to 4-
digit resolution based on high density SNP genotyping
(Leslie et al. 2008). Infectious diseases associated with
the MHCs of a variety of species are covered in detail
in this volume.
There has been progress in understanding one set of
MHC-associated conditions, namely drug sensitivities
(Illing et al. 2012). This topic is reviewed here by the
key contributors to understanding the molecular mecha-
nisms behind the pharmacogenomics; McClusky this
volume. Abacavir sensitivity is strongly associated with
HLA-B*057:01. Purification of HLA-B*057:01 from
cells treated with abacavir indicated that the drug bound
to the antigen-binding cleft, pushing up peptides and
thereby leading to stimulation of a set of T cells. The
drug non-covalently bound to the B*057:01 molecule,
breaking tolerance (Illing et al. 2012).
Other conditions linked to the MHC region include cancers
of a suspected viral aetiology, such as nasopharyngeal carci-
noma and Hodgkin’s lymphoma. There are reports of a variety
of other condition such as schizophrenia and complement C4
genes, embedded in the MHC (Sekar et al. 2016).
Receptors
As discussed above, antigen presentation is probably the
main raison d’etre of class I and class II molecules. Both
classes I and II interact with T cells, through their recep-
tors, which result in modulation of immune responses in
a peptide-dependent fashion. But, there are a variety of
ways in which the information from these molecules may
be interpreted. Other sets of receptors may detect differ-
ences in MHC classes I and II in peptide-dependent and
peptide-independent ways resulting in ‘missing-self’, re-
leasing inhibition by inhibitory receptors on NK or other
cells, as discussed in this issue.
KIRs bind sets of HLA molecules generally assumed to be
associated with peptide (Saunders et al. 2015). Changes in the
peptide associated with class I molecules can prevent inhibi-
tion of NK activation (Fadda et al. 2010). In this regard, they
have peptide:HLA specificity, which may be associated with
effects on infections with viruses. Examples include the inhib-
itory receptor KIR2DL3 and hepatitis C and the activating
receptor KIR3DS1 and HIV (Buchanan et al. 2015; Martin
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and Carrington 2013). The main paradigm for Natural Killer
cells detecting the presence of class I molecules is encapsulat-
ed in the missing self hypothesis, whereby loss of class I or
failure to bind to inhibitory receptors signifies that the cell has
been compromised. Canaries were taken down coalmines as a
warning system for toxic gasses, particularly carbon monox-
ide. In a similar way, class I molecules are sentinels of un-
healthy or infected cells. Some KIR-related receptors on cells
of monocyte lineages (LILR, ILR, ILT) also influence im-
mune responses.
Cancer immunosurveillance
There is some evidence that the immune system naturally
protects against cancer (Corthay 2014). However, the inci-
dence of cancer only increases marginally when acquired im-
munity is disabled, and it has also been proposed that inflam-
mation may promote tumour growth (Mantovani et al. 2008).
In spite of this, initiatives to direct adaptive Tcell immunity
to cancer cells are starting to show promise. There has been
some clinical success with three approaches: (a) cancer vacci-
nation; (b) with antibodies that stimulate T cells by blocking
inhibitory receptor interactions, such as anti-CTLA4, PD1 or
PDL1; and (c) with adoptive transfer of anti-tumour T cells.
These techniques depend on exploiting T cells from the pa-
tients that specifically recognise tumour antigens through
MHC molecules. They may be combined to produce greater
efficacy.
Before discussing issues associated with MHC and
immunosurveillance, it is worth considering the scope of
HLA expression. The textbook view is that class I is expressed
on all nucleated cells, with a few notable exceptions, and that
class II molecules are restricted in expression to professional
antigen presenting cells unless induced by cytokines such as
gamma-interferon. This simplistic viewhas been questioned as
there is evidence for considerable variation in HLA levels in
different tissues. There is debate over whether loss of HLA
expression in tumours is governed by immunoselection or
whether it is simply a by-product of genomic instability
(Campoli et al. 2012).
There are at least three major problems in terms of
specificity:
1. Loss of HLA class I or peptide epitope expression—
immunoediting
There is abundant evidence for loss of expression of HLA
class I as an escape mechanism on a variety of tumours
(Garrido et al. 2016). A number of strategies have been sug-
gested to overcome HLA class I defects if they are due to
reversible mechanisms and not permanent gene deletion
(Lampen and van Hall 2011). These include addition of
cytokines or the use of epigenetic modifiers such as inhibitors
of DNA methyl transferase or histone deacetylase. However,
~30–40% of tumours appear to have a more permanent loss of
HLA class I, due for example to loss of β2microglobulin. In
principle, NK cells may be capable of targeting HLA-negative
tumours, if they are stimulated by IL-12/IL-18 treatment. It
has been proposed that tumours with a more complex genome
have a higher frequency of total HLA class I loss (Rashidi
2014). There are also data suggesting that there may not be a
simple relationship between class I and cancer survival
(Powell et al. 2012).
2. Identification of epitopes
After some early work identifying mouse tumour antigens,
pioneering work from Thierry Boon’s laboratory revealed
novel epitopes in human cancers (Coulie et al. 2014). The first
of these, derived from the MAGEA1 gene, was a normal
cellular component from a gene family. Other anti-tumour
cytotoxic T cells (CTLs) were shown to recognise peptides
from antigens that were mutated in the tumour cells. In mela-
noma, some CTLs and some CD4 T cells recognised peptides
from proteins specifically expressed in the melanoma cells. It
was realised that numerous genes are likely to be mutated in
cancer, producing neo-epitopes that could be presented by the
specific MHC allele in the patient. Computer algorithms were
generated to identify likely peptide sequences that could be
presented by the host’s MHC molecules. In essence, there are
four types of tumour antigen recognised by T cells: (a) viral
antigens, in cervical carcinoma or hepato-carcinoma, where
there is a clear viral aetiology; (b) antigens from mutated
genes, by a variety of mechanisms, including frame-shift, sin-
gle amino acid changes or protein extension due to loss of the
correct stop codon; (c) cancer-germline genes, that also used
to be called oncofetal antigens. These are normal proteins
expressed in tumours but not in normal somatic tissues.
They may have become activated in tumours due to demeth-
ylation of their promoter. (d) Proteins over-expressed in tu-
mours. An example of this is MUC1, a protein over-expressed
on most adenocarcinomas.
Recent work indicates that peptide targets for CTLs are not
randomly distributed amongst the whole range of cellular pro-
teins but rather are focussed onto less than 50% of genes, from
selective regions of the genome (Pearson et al. 2016). Some
proteins are responsible for several different peptide antigens,
and peptides may be derived from non-canonical reading
frames (Laumont et al. 2016). Algorithms are being developed
to facilitate prediction of relevant self peptides. Another com-
plication is the finding that a large number of HLA-associated
peptides are ‘spliced’ products of the proteasome (Liepe et al.
2016). There are data that suggest tumours that respond best to
immunosurveillance have the highest mutagenic load
(Alexandrov et al. 2013).
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3. Autoimmune side effects
It is difficult to predict whether T cell immunotherapy to a
specific antigen will be harmful, but several cases have been
documented (Coulie et al. 2014). Most immunotherapeutic
approaches to cancer have concentrated on T cells, but there
is emerging interest in NK cells in the last few years (Childs
and Carlsten 2015). Clearly, there is a long way to go in
developing better tumour immunotherapy. There is evi-
dence that the local tumour environment is immuno-
suppressive. It is possible that therapeutic intervention in-
vokes immunostimulation, awakening quiescent T cells al-
ready in the tumour environment (Coulie et al. 2014).
Introducing inhibitors of immunosuppression may help to
complement some of the approaches.
Contributions to the subject of HLA and cancer are includ-
ed in this volume.
Peptide databases: iedb (http://www.iedb.org/);
SYFPEITHI (http://www.syfpeithi.de/); http://www.imtech.
res.in/raghava/mhcbn/.
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